Dublin, Jan. 31, 2019 (GLOBE NEWSWIRE) -- The "Peanut Allergy - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. "Peanut Allergy - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Peanut Allergy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Peanut Allergy Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for Peanut Allergy The report assesses the active Peanut Allergy pipeline products by developmental stage, product type, molecule type, and administration route. Scope of the report

  • The report provides a snapshot of the pipeline development for the Peanut Allergy
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Peanut Allergy
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Peanut Allergy
  • The report also covers the dormant and discontinued pipeline projects related to the Peanut Allergy

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Peanut Allergy to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Peanut Allergy therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered: 1. Report Introduction 2. Peanut Allergy Overview 3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Peanut Allergy

4. Comparative Analysis 5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Appendix Companies Mentioned

  • Adverum Biotechnologies Inc
  • Aimmune Therapeutics Inc
  • Alfacyte Ltd
  • Allergy Therapeutics Plc
  • AnaptysBio Inc
  • ASIT Biotech SA
  • Astellas Pharma Inc
  • BioLingus AG
  • DBV Technologies SA
  • HAL Allergy BV

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8...eanut?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Allergy Drugs